Merck & Co. 2027 increased by 58.3% to $3.80B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 58.3%, from $2.40B to $3.80B. Over 5 years (FY 2020 to FY 2025), 2027 shows an upward trend with a 20.4% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Lower projected expenses indicate a reduction in the drag on future net income as assets become fully amortized.
This represents the projected amortization expense for finite-lived intangible assets for the year 2027. These assets ty...
Standard disclosure for banks with significant historical acquisition activity.
other_finite_lived_intangible_assets_amortization_expens_a31c97| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $1.70B | $1.80B | $1.80B | $2.40B | $3.80B |
| QoQ Change | — | +5.9% | +0.0% | +33.3% | +58.3% |
| YoY Change | — | +5.9% | +0.0% | +33.3% | +58.3% |